Compound Detail
CHEMBL584
NELFINAVIR 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
Basic Information
| ChEMBL ID | CHEMBL584 |
| Name | NELFINAVIR |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | QAGYKUNXZHXKMR-HKWSIXNMSA-N |
| Therapeutic | ✓ Yes |
47
Targets
275
Activities
4
Assay Types
11
PK Parameters
20
Publications
2
Known Names
20
Indications
Molecular Properties
567.8
MW (Da)
4.75
ALogP
6
HBA
4
HBD
101.9
PSA (Ų)
0.33
QED
1
Ro5 Violations
9
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 1997 |
| Availability | Prescription |
| Chirality | Single Enantiomer |
Indications
Acquired Immunodeficiency Syndrome Carcinoma Diarrhea HIV Infections Virus Diseases Carcinoma, Non-Small-Cell Lung Lupus Erythematosus, Systemic Multiple Myeloma Uterine Cervical Dysplasia Carcinoma, Renal Cell Colorectal Neoplasms Glioblastoma Lung Neoplasms Lymphoma Neoplasms Pancreatic Neoplasms Paraganglioma Sepsis Uterine Cervical Neoplasms Vulvar Neoplasms
ATC Classification
J05AE04
nelfinavir
Level 1: ANTIINFECTIVES FOR SYSTEMIC USE
Level 2: ANTIVIRALS FOR SYSTEMIC USE
Activity Summary
IC50 115 meas. best 8.72
EC50 106 meas. best 8.78
Ki 49 meas. best 11.0
Kd 5 meas. best 8.79
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Human immunodeficiency virus type 1 protease CHEMBL243 | Ki | 11.0 | 8.6341 | 0.0 | 17 |
| Protease CHEMBL2366517 | Ki | 10.15 | 9.455 | 0.1 | 4 |
| Unchecked CHEMBL612545 | Ki | 9.55 | 6.485 | 0.3 | 12 |
| Human immunodeficiency virus type 1 protease CHEMBL243 | Kd | 8.79 | 8.79 | 1.6 | 2 |
| Human immunodeficiency virus 1 CHEMBL378 | EC50 | 8.78 | 6.9499 | 1.7 | 89 |
| Protease CHEMBL2366517 | IC50 | 8.72 | 8.385 | 1.9 | 2 |
| NON-PROTEIN TARGET CHEMBL3879801 | IC50 | 8.7 | 6.81 | 2.0 | 2 |
| Human immunodeficiency virus 1 CHEMBL378 | IC50 | 8.7 | 7.6065 | 2.0 | 17 |
| Protease CHEMBL2366517 | Kd | 8.52 | 8.1367 | 3.0 | 3 |
| Human immunodeficiency virus 2 CHEMBL380 | IC50 | 7.7 | 6.4281 | 20.0 | 26 |
| Human immunodeficiency virus CHEMBL613758 | EC50 | 7.64 | 7.64 | 23.0 | 1 |
| Human immunodeficiency virus 2 CHEMBL380 | EC50 | 7.52 | 6.96 | 30.0 | 11 |
| Simian immunodeficiency virus CHEMBL613499 | EC50 | 7.3 | 7.3 | 50.0 | 1 |
| MT4 CHEMBL388 | IC50 | 7.3 | 6.6 | 50.0 | 5 |
| Human immunodeficiency virus CHEMBL613758 | IC50 | 6.5 | 6.425 | 320.0 | 2 |
| ATP-dependent translocase ABCB1 CHEMBL4302 | IC50 | 6.46 | 5.5222 | 350.0 | 9 |
| Cytochrome P450 3A4 CHEMBL340 | Ki | 6.32 | 6.16 | 480.0 | 2 |
| Human immunodeficiency virus type 1 protease CHEMBL243 | IC50 | 6.28 | 6.28 | 530.0 | 1 |
| Cytochrome P450 3A4 CHEMBL340 | IC50 | 6.26 | 5.98 | 550.0 | 2 |
| Cytochrome P450 3A5 CHEMBL3019 | Ki | 6.24 | 6.24 | 570.0 | 1 |
| SARS-CoV CHEMBL4303836 | EC50 | 6.11 | 6.11 | 770.0 | 1 |
| Unchecked CHEMBL612545 | IC50 | 5.73 | 5.08 | 1881.0 | 4 |
| ATP-dependent translocase ABCB1 CHEMBL2573 | IC50 | 5.64 | 5.64 | 2300.0 | 2 |
| SARS-CoV-2 CHEMBL4303835 | IC50 | 5.48 | 5.48 | 3300.0 | 1 |
| dengue virus type 2 CHEMBL613966 | IC50 | 5.46 | 5.46 | 3500.0 | 1 |
| Unchecked CHEMBL612545 | EC50 | 5.46 | 5.46 | 3500.0 | 1 |
| Progesterone receptor CHEMBL1909044 | Ki | 5.24 | 5.24 | 5804.0 | 1 |
| Mu-type opioid receptor CHEMBL233 | Ki | 5.23 | 5.23 | 5859.0 | 1 |
| D(1A) dopamine receptor CHEMBL2056 | Ki | 5.19 | 5.19 | 6467.0 | 1 |
| Tyrosine-protein kinase Fyn CHEMBL1841 | IC50 | 5.1 | 5.1 | 7971.0 | 1 |
| Adenosine receptor A3 CHEMBL256 | Ki | 5.08 | 5.08 | 8363.0 | 1 |
| Sodium-dependent noradrenaline transporter CHEMBL222 | Ki | 5.06 | 5.06 | 8779.0 | 1 |
| Sodium-dependent noradrenaline transporter CHEMBL222 | IC50 | 5.05 | 5.05 | 8852.0 | 1 |
| Leishmania donovani CHEMBL367 | IC50 | 5.02 | 4.855 | 9620.0 | 2 |
| Substance-K receptor CHEMBL2327 | Ki | 5.01 | 5.01 | 9793.0 | 1 |
| Trypanosoma cruzi CHEMBL368 | IC50 | 4.99 | 4.99 | 10230.0 | 1 |
| Plasmodium falciparum CHEMBL364 | IC50 | 4.98 | 4.98 | 10440.0 | 1 |
| Bile salt export pump CHEMBL6020 | IC50 | 4.93 | 4.93 | 11800.0 | 3 |
| Trypanosoma cruzi CHEMBL368 | EC50 | 4.92 | 4.92 | 12000.0 | 1 |
| Sodium-dependent dopamine transporter CHEMBL238 | Ki | 4.91 | 4.91 | 12335.0 | 1 |
| Voltage-gated inwardly rectifying potassium channel KCNH2 CHEMBL240 | IC50 | 4.9 | 4.9 | 12589.2 | 1 |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 CHEMBL5393 | IC50 | 4.9 | 4.9 | 12500.0 | 2 |
| D(1A) dopamine receptor CHEMBL2056 | IC50 | 4.89 | 4.89 | 12935.0 | 1 |
| Polyunsaturated fatty acid lipoxygenase ALOX15 CHEMBL4358 | IC50 | 4.86 | 4.86 | 13797.0 | 1 |
| Kappa-type opioid receptor CHEMBL237 | Ki | 4.84 | 4.84 | 14398.0 | 1 |
| Mu-type opioid receptor CHEMBL233 | IC50 | 4.84 | 4.84 | 14432.0 | 1 |
| Adenosine receptor A3 CHEMBL256 | IC50 | 4.83 | 4.83 | 14796.0 | 1 |
| Sodium-dependent dopamine transporter CHEMBL238 | IC50 | 4.81 | 4.81 | 15525.0 | 1 |
| Mitogen-activated protein kinase 14 CHEMBL260 | IC50 | 4.74 | 4.74 | 18224.0 | 1 |
| Trypanosoma brucei rhodesiense CHEMBL612348 | IC50 | 4.69 | 4.69 | 20610.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| AUC | 44163.48 | ng.hr.mL-1 | Homo sapiens |
| Cmax | 7040.0 | nM | Homo sapiens |
| F | 52.0 | % | Rattus norvegicus |
| F | 31.0 | % | Canis lupus familiaris |
| F | 34.0 | % | Simiiformes |
| Fu | - | - | Rattus norvegicus |
| Fu | 0.024 | - | Homo sapiens |
| Fu | 0.00072 | - | Rattus norvegicus |
| Fu | 0.003 | - | Rattus norvegicus |
| Fu | 0.001 | - | Rattus norvegicus |
| Vd | 860.0 | L.kg-1 | Rattus norvegicus |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 17638694 | 10.1128/aac.00149-07 | Human immunodeficiency virus 1 | 53 |
| 18227188 | 10.1128/aac.01284-07 | Human immunodeficiency virus 2 | 36 |
| 18955518 | 10.1128/aac.00689-08 | Human immunodeficiency virus 1 | 33 |
| 17101675 | 10.1128/aac.00690-06 | Human immunodeficiency virus 1 | 33 |
| 18598016 | 10.1021/jm8002334 | Human immunodeficiency virus type 1 protease | 26 |
| 17371811 | 10.1128/aac.01413-06 | Human immunodeficiency virus 1 | 24 |
| 20404123 | 10.1128/aac.01828-09 | Human immunodeficiency virus 1 | 19 |
| 17981045 | 10.1016/j.bmc.2007.10.062 | Human immunodeficiency virus 1 | 17 |
| 22194678 | 10.1371/journal.pcbi.1002310 | Hepatotoxicity | 14 |
| 18598016 | 10.1021/jm8002334 | Unchecked | 12 |
| 15646539 | 10.1016/s0399-8320(04)95062-2 | Unchecked | 11 |
| 16913714 | 10.1021/jm060561m | Human immunodeficiency virus 1 | 11 |
| 18426195 | 10.1021/jm701555p | Human immunodeficiency virus 1 | 11 |
| 17576848 | 10.1128/aac.00146-07 | Human immunodeficiency virus 2 | 10 |
| 20439612 | 10.1128/aac.01766-09 | Human immunodeficiency virus 1 | 10 |
| 17116674 | 10.1128/aac.00870-06 | Human immunodeficiency virus 2 | 9 |
| 12699389 | 10.1021/jm021012t | ATP-dependent translocase ABCB1 | 9 |
| 21051535 | 10.1124/dmd.110.034629 | ADMET | 9 |
| 18212102 | 10.1128/aac.01132-07 | Human immunodeficiency virus 1 | 9 |
| 18541726 | 10.1128/aac.00210-08 | Human immunodeficiency virus 1 | 8 |
Data from ChEMBL 36 via Core Engine